616464 InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem

616464
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₂₂H₁₆N₄O₃ • 2H₂O301836-41-9

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
616464-5MGCN
Retrieving availability...
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220). The solid form of this compound (Cat. No. 616461) is also available.
      Catalogue Number616464
      Brand Family Calbiochem®
      References
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      Product Information
      CAS number301836-41-9
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Hill FormulaC₂₂H₁₆N₄O₃ • 2H₂O
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Hygroscopic Hygroscopic
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ TGF-β RI Kinase Inhibitor VI, SB431542, CAS 301836-41-9, is a 100 mM solution in DMSO.A cell-permeable, selective inhibitor of SMAD2 phosphorylation (greater than 90% inhibition at 10 µM).
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/38

      Irritating to eyes and skin.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      InSolution™ TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem Certificates of Analysis

      TitleLot Number
      616464

      References

      Reference overview
      Ikushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision01-February-2012 RFH
      DescriptionA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220).
      FormLiquid
      FormulationA 100 mM (5 mg/119 µl) solution of SB431542 (Cat. No. 616461) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number301836-41-9
      Chemical formulaC₂₂H₁₆N₄O₃ • 2H₂O
      Structure formulaStructure formula
      Purity≥97% by HPLC
      Storage -20°C
      Hygroscopic
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Irritant
      ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
      Lin, T., et al. 2009. Nat. Methods 6, 805.
      Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
      Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
      Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
      Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.